HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Communiqués Hansoh Pharmaceutical Group Company Limited Deutsche Boerse AG

Actions

3KY

KYG549581067

Marché Fermé - Deutsche Boerse AG Autres places de cotation 15:29:01 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,88 ^EUR	-4,57 %		-.--%	+14,63 %

14/06	Hansoh Pharmaceutical réduit le prix de conversion des obligations convertibles	MT
30/04	Hausse de 27% des bénéfices de Hansoh Pharmaceutical pour 2023	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	24/01	AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award	19/10/23	AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia	25/09/23	AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China	20/07/23	AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan	27/09/22	AQ
Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021	29/03/22	PU
Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China	12/10/21	AQ
SCYNEXIS : Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	14/09/21	AQ
SCYNEXIS : Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	13/09/21	AQ
Hansoh Pharmaceutical : Accelerate Benefits for Hepatitis B Patients! Hansoh Pharma's New Class 1 Drug Hengmu (Tenofovir Amibufenamide Tablets) Prescribed for the First Time in China	06/07/21	AQ
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	13/05/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"	10/05/21	PU
Hansoh Pharmaceutical : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 2021	27/04/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "LENALIDOMIDE CAPSULE"	01/04/21	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "EMPAGLIFLOZIN TABLETS"	31/07/20	PU
Hansoh Pharmaceutical : INSIDE INFORMATION - LICENSE AGREEMENT WITH EQRX	23/07/20	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Bourse
Actions
Action 3692
Action 3KY
Actualités Hansoh Pharmaceutical Group Company Limited
Communiqués

Sécurisez et Augmentez les Rendements de vos Investissements grâce à l'Accompagnement de Nos Experts

Sécuriser mes Investissements

fermer